These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 33939886)

  • 1. A meta-analysis and cost-minimization analysis of bivalirudin versus heparin in high-risk patients for percutaneous coronary intervention.
    Sun KX; Cui B; Cao SS; Wang WJ; Yu F; Wang JW; Ding Y
    Pharmacol Res Perspect; 2021 May; 9(3):e00774. PubMed ID: 33939886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic evaluation of bivalirudin with provisional glycoprotein IIB/IIIA inhibition versus heparin with routine glycoprotein IIB/IIIA inhibition for percutaneous coronary intervention: results from the REPLACE-2 trial.
    Cohen DJ; Lincoff AM; Lavelle TA; Chen HL; Bakhai A; Berezin RH; Jackman D; Sarembock IJ; Topol EJ
    J Am Coll Cardiol; 2004 Nov; 44(9):1792-800. PubMed ID: 15519009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Outcomes of Bivalirudin Versus Heparin in Elderly Patients Undergoing Percutaneous Coronary Intervention: a Systematic Review and Meta-analysis of Randomized Controlled Trials.
    Meng S; Xu J; Guo L; Huang R
    Cardiovasc Drugs Ther; 2020 Feb; 34(1):101-111. PubMed ID: 32100149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bivalirudin in percutaneous coronary intervention, is it the anticoagulant of choice?
    Mahmoud A; Saad M; Elgendy AY; Abuzaid A; Elgendy IY
    Cardiovasc Ther; 2015 Aug; 33(4):227-35. PubMed ID: 25879426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bivalirudin is associated with improved clinical and economic outcomes in heart failure patients undergoing percutaneous coronary intervention: Results from an observational database.
    Pinto DS; Kohli P; Fan W; Kirtane AJ; Kociol RD; Meduri C; Deliargyris EN; Prats J; Reynolds MR; Stone GW; Michael Gibson C
    Catheter Cardiovasc Interv; 2016 Feb; 87(3):363-73. PubMed ID: 26011467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bivalirudin versus heparin in women undergoing percutaneous coronary intervention: A systematic review and meta-analysis of randomized clinical trials.
    Saad M; Nairooz R; Rashed A; Abdelaziz HK; Mentias A; Abbott JD
    Cardiovasc Revasc Med; 2017 Sep; 18(6):418-424. PubMed ID: 28291727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bivalirudin versus heparin in patients planned for percutaneous coronary intervention: a meta-analysis of randomised controlled trials.
    Cavender MA; Sabatine MS
    Lancet; 2014 Aug; 384(9943):599-606. PubMed ID: 25131979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anticoagulant therapy during primary percutaneous coronary intervention for acute myocardial infarction: a meta-analysis of randomized trials in the era of stents and P2Y12 inhibitors.
    Bangalore S; Toklu B; Kotwal A; Volodarskiy A; Sharma S; Kirtane AJ; Feit F
    BMJ; 2014 Nov; 349():g6419. PubMed ID: 25389143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of safety and efficacy of bivalirudin versus unfractionated heparin in percutaneous peripheral intervention: a single-center experience.
    Sheikh IR; Ahmed SH; Mori N; Gupta A; Mewissen M; Allaqaband S; Bajwa T
    JACC Cardiovasc Interv; 2009 Sep; 2(9):871-6. PubMed ID: 19778776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gender-based outcomes of bivalirudin versus heparin in patients undergoing percutaneous coronary interventions: Meta-analysis of randomized controlled trials.
    Mina GS; Firouzbakht T; Modi K; Dominic P
    Catheter Cardiovasc Interv; 2017 Nov; 90(5):735-742. PubMed ID: 28339139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bivalirudin versus heparin in contemporary percutaneous coronary interventions for patients with acute coronary syndrome: a systematic review and meta-analysis.
    Zhang J; Chen Z; Wang D; Li C; Luo F; He Y
    Cardiol J; 2024; 31(2):309-320. PubMed ID: 37964648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bivalirudin in percutaneous coronary intervention for chronic total occlusion: A single-center pilot study.
    Li C; Xu R; Shen Y; Dai Y; Zhang F; Ma J; Ge L; Qian J; Ge J
    Catheter Cardiovasc Interv; 2018 Mar; 91(4):679-685. PubMed ID: 28766879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention in high-bleeding-risk patients with acute coronary syndrome in contemporary practice.
    Zhang Y; Zhang Y; Liu Z; Zhang B; Liu G; Chen K
    Biomed Pharmacother; 2020 Oct; 130():110758. PubMed ID: 34321166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of anticoagulation strategy with bivalirudin or heparin on nonaccess site bleeding in percutaneous coronary interventions: A meta-analysis of randomized trials.
    Verdoia M; Barbieri L; Parodi G; Bellandi B; Schaffer A; Suryapranata H; De Luca G
    Catheter Cardiovasc Interv; 2017 Oct; 90(4):553-565. PubMed ID: 28471057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short- and long-term outcomes in diabetes patients undergoing percutaneous coronary intervention with bivalirudin compared with heparin and glycoprotein IIb/IIIA inhibitors: A meta-analysis of randomized trials.
    Nairooz R; Sardar P; Amin H; Chatterjee S; Helmy T; Naidu SS
    Catheter Cardiovasc Interv; 2015 Sep; 86(3):364-75. PubMed ID: 25914388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of bivalirudin versus heparin in patients undergoing percutaneous coronary intervention: A meta-analysis of randomized controlled trials.
    Zhang S; Gao W; Li H; Zou M; Sun S; Ba Y; Liu Y; Cheng G
    Int J Cardiol; 2016 Apr; 209():87-95. PubMed ID: 26882192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meta-analysis of bivalirudin versus heparin in transradial coronary interventions.
    Kheiri B; Rao SV; Osman M; Simpson TF; Barbarawi M; Zayed Y; Dhillon HN; Alkhouli M; Golwala H; Zahr F; Bhatt DL; Stone GW; Cigarroa JE
    Catheter Cardiovasc Interv; 2020 Nov; 96(6):1240-1248. PubMed ID: 32091668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of bivalirudin versus heparin in patients with diabetes mellitus undergoing percutaneous coronary intervention: A meta-analysis of randomized controlled trials.
    Zhang J; Yang X
    Medicine (Baltimore); 2017 Jul; 96(29):e7204. PubMed ID: 28723739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Meta-analysis of randomized clinical trials comparing bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitors in patients undergoing percutaneous coronary intervention and in patients with ST-segment elevation myocardial infarction.
    Nairooz R; Sardar P; Amin H; Swaminathan RV; Kim LK; Chatterjee S; Feldman DN
    Am J Cardiol; 2014 Jul; 114(2):250-9. PubMed ID: 24890986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial.
    Han Y; Guo J; Zheng Y; Zang H; Su X; Wang Y; Chen S; Jiang T; Yang P; Chen J; Jiang D; Jing Q; Liang Z; Liu H; Zhao X; Li J; Li Y; Xu B; Stone GW;
    JAMA; 2015 Apr; 313(13):1336-46. PubMed ID: 25775052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.